Your breath becomes a window into what's happening inside
For generations, the early detection of blood cancer has been constrained not by a lack of scientific understanding, but by the weight of logistics — the cost of imaging, the scarcity of pathologists, the long weeks of waiting. Researchers at Queen Mary University of London, working with Cambridge-based Owlstone Medical, have found that the breath itself carries a molecular signature of disease, one that a portable device might one day read in seconds. This discovery does not yet change how patients are diagnosed, but it opens a door that cost, geography, and time have long kept closed.
- Blood cancer remains one of medicine's most elusive early targets — its symptoms are vague, its confirmation process slow, and its infrastructure demands far beyond what many regions can provide.
- A study of 46 blood cancer patients found measurably elevated oxidative stress molecules in their exhaled breath, particularly among those with aggressive high-grade lymphoma, marking the first time breath analysis has detected blood cancer at all.
- The Breath Biopsy technology developed by Owlstone Medical uses mass spectrometry to build a chemical fingerprint from thousands of molecular fragments in a single breath sample — portable, affordable, and requiring no specialized training.
- Researchers are already working to compress the ten-minute breath collection window to just seconds, a threshold that would make routine clinic-based screening genuinely feasible.
- Significant work remains — mapping how cancer cells release these molecules into breath, identifying which lymphoma subtypes are detectable, and refining accuracy — but the biological signal has been confirmed and the scientific foundation is in place.
Blood cancers are difficult to catch early. Their symptoms — fatigue, weight loss, a general sense of something being wrong — could point to almost anything, and confirming a diagnosis typically requires weeks of imaging, biopsies, and specialist consultations. In much of the world, that infrastructure simply does not exist, making early detection a privilege rather than a standard of care.
Researchers at Queen Mary University of London, partnering with Cambridge-based Owlstone Medical, have now demonstrated something quietly remarkable: the breath of a person with blood cancer carries a distinct molecular signature. Their study collected exhaled breath samples from 46 blood cancer patients and 28 healthy controls, then used mass spectrometry to analyze thousands of molecular fragments from each sample. Patients with high-grade lymphoma — among the most aggressive blood cancers — exhaled significantly elevated levels of molecules linked to oxidative stress, the cellular damage that accompanies cancer's development.
The technology behind this, called Breath Biopsy, is portable and requires no specialized training to operate. Published in HemaSphere, the research represents the first demonstration that breath analysis can detect blood cancers at all. Breath samples currently take ten minutes to collect, but the team is already working to reduce that to seconds — the speed at which routine screening becomes practical.
The vision articulated by lead researcher Dr. John Riches is straightforward: a doctor conducts a breath test in the clinic room and has answers within seconds, rather than sending a patient away for costly scans and waiting days for results. The diagnostic bottleneck in blood cancer is not scientific — it is logistical and economic. A breath test removes the cost of imaging, the need for trained pathologists, and the burden of time, all at once.
Considerable work remains before this becomes a clinical tool. Researchers must map precisely how cancer cells release these molecules into breath, determine which cancer subtypes are detectable, and refine the test's accuracy to avoid false results. But the signal is real, the technology functions, and the path from laboratory finding to widespread screening tool — though long — has now begun.
Blood cancers are notoriously hard to catch early. Fatigue, weight loss, the vague malaise that sends someone to their doctor—these symptoms could mean almost anything. By the time a diagnosis arrives, it has usually taken weeks or months of imaging scans, biopsies, specialist consultations, and the mounting anxiety that comes with waiting. For patients in parts of the world where such infrastructure barely exists, early detection becomes nearly impossible. Researchers at Queen Mary University of London have now identified a simpler path: molecules in your breath.
The study, conducted in partnership with Owlstone Medical, a Cambridge-based company that developed a technology called Breath Biopsy, collected exhaled breath samples from 46 people living with blood cancer and 28 healthy controls. The researchers used mass spectrometry to parse thousands of molecular fragments from each breath sample, building a kind of chemical fingerprint unique to disease. What they found was striking: patients with high-grade lymphoma, one of the more aggressive blood cancers, exhaled significantly elevated levels of molecules associated with oxidative stress—the cellular damage that accompanies cancer development. The breath, in other words, was telling a story the body had been trying to hide.
The implications are substantial. A breathalyser device is portable, affordable, and requires no specialized training to operate. In clinics without access to imaging equipment or pathology labs, it could mean the difference between catching cancer early and discovering it only when treatment becomes far more difficult. The research, published in HemaSphere, represents the first time breath analysis has been shown to detect blood cancers at all. The team collected breath for ten minutes per sample, but they are already working to compress that window to just a few seconds—the kind of speed that would make routine screening feasible.
Dr. John Riches, who led the research, described the vision plainly: instead of sending patients away for expensive scans and then waiting days for results, a doctor could conduct a breath test in the clinic room itself and have answers within seconds. That shift—from a process measured in weeks to one measured in minutes—would reshape how blood cancers are caught and treated. The current diagnostic bottleneck is not scientific; it is logistical and economic. Imaging is costly. Biopsies require trained pathologists. Results take time. A breath test removes all three barriers at once.
The work ahead is substantial. Researchers need to understand precisely how cancer cells release these molecules into the bloodstream and then into exhaled breath. They need to determine which subtypes of lymphoma are most detectable through this method, and whether the approach works for other blood cancers entirely. They need to refine the sensitivity and specificity of the test so that it catches disease without generating false alarms. But the foundation is laid. The molecules are there. The technology works. What remains is the careful, methodical work of turning a laboratory finding into a tool that changes how millions of people are screened and treated.
Notable Quotes
Rather than sending patients away for costly scans and waiting for results, doctors may be able to conduct a quick breath test in their clinic room with results within seconds— Dr. John Riches, lead researcher
The Hearth Conversation Another angle on the story
Why is early detection of blood cancer so difficult right now?
Because the symptoms are so generic—tiredness, weight loss—that patients and doctors often miss them until the cancer is advanced. And the tests that do catch it are expensive, slow, and not available everywhere. By the time you have a diagnosis, weeks have passed.
So the breath test is faster. But why would cancer show up in your breath at all?
Cancer cells create oxidative stress—cellular damage. That stress produces molecules that enter the bloodstream and eventually get exhaled. Your breath becomes a window into what's happening inside your body.
How reliable is it? Could it give false positives?
That's what they're still working on. The study proved the concept works, but they need to improve sensitivity and specificity so the test catches real disease without alarming people unnecessarily.
What changes if this becomes routine?
Everything. A doctor could test you in seconds instead of sending you for scans. In countries without imaging infrastructure, it means early detection becomes possible. Treatment outcomes improve dramatically when you catch cancer early.
How soon could this be available?
They're still optimizing it. They want to cut collection time from ten minutes to seconds. But the science is sound. It's a matter of refinement and validation now.